Published in Physician Law Weekly, June 2nd, 2004
This phase II study is conducted under a CRADA between CollaGenex and the National Cancer Institute (NCI). The principal investigator is Bruce Dezube, MD, of Beth Israel Deaconess Medical Center at the Harvard Medical School. Seventy five patients were randomized to receive Col-3 at a dose of either 50 mg or 100 mg per day. The study is still ongoing with 12 patients in the low dose group and 10...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly